Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $755.50
Regulatory News: Santen Pharmaceutical Co., Ltd. (“Santen”) and Novagali Pharma SA (“Novagali”) announced today the success...
Regulatory News: Novagali Pharma (Paris:NOVA), a pharmaceutical company that develops and markets innovative ophthalmic...
Regulatory News: Following the press release of September 28, 2011, in accordance with articles 223-2 and 223-6 of the...
Regulatory News: Santen Pharmaceutical Co., Ltd. (Osaka, Ticker Code 4536JP) (hereafter “Santen”), a leading Japanese...
Regulatory News: Novagali Pharma (Paris:NOVA) announced today US phase II positive results on the efficacy and safety of...
Regulatory News: Novagali (Paris:NOVA): Novagali Pharma, a pharmaceutical company that develops and sells innovative...
Regulatory News: Approval of all the resolutions proposed at the Combined General Meeting of the shareholders on June 22...
Regulatory News: Novagali Pharma (Paris:NOVA), a pharmaceutical company that develops innovative ophthalmic products, can...
Regulatory News: Novagali Pharma, a pharmaceutical company that develops innovative ophthalmic products, today announces its...
Regulatory News: Cash burn in line with expectations Major clinical milestones since the IPO Unique status as a...
Regulatory News: Novagali Pharma (Paris:NOVA), a pharmaceutical company that develops innovative ophthalmic products...
Regulatory News: Novagali Pharma (Paris:NOVA), a pharmaceutical company that develops innovative ophthalmic products, today...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.